Abstract. Areas of low endemicity of Hansen's disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections. Managing this disease in these areas of low endemicity is difficult, especially in observing for relapse. The accurate diagnosis of relapse is imperative so that appropriate therapy can be promptly reinstituted and unnecessary treatment can be avoided. To assess treatment failures in an area of low endemicity, we retrospectively evaluated 113 patients with Hansen's disease treated in southern Texas. Of 57 patients who completed therapy, 11 were later restarted on medications for this disease for presumed relapse. However, nine of the 11 were found not to have true relapses of Hansen's disease. The accurate diagnosis of relapse of this disease is essential not only in the individual patient but also for prospective treatment trials to establish best practices.
The rarity of this disease in areas of low endemicity complicates its clinical management, particularly in monitoring for relapse. Relapse of Hansen's disease occurs in patients after they have completed an appropriate course of therapy. Patients have a recurrence of active bacillary growth resulting in reappearance of compatible signs and symptoms of this disease. 1, [3] [4] [5] Various features help define relapse. These include clinical assessment (compatible signs or symptoms), bacteriologic status (bacteriologic index from slit skin smears, acidfast staining of biopsy material, mouse footpad culture for Hansen's bacilli and, possibly, DNA-based genetic detection), and histologic status (presence and nature of inflammation). There appears to be no clear consensus which features most effectively identify relapse. 4 In an attempt to better define the characteristics of presumed relapse in our south Texas Hansen's disease clinic, we retrospectively reviewed 113 patients with this disease who had been cared for in the previous 10 years. Relapse was defined as a combination of new signs or symptoms and the presence of new acid-fast bacilli on skin or nerve biopsy samples. Patients must have completed a course of therapy for this disease. These courses were variable and did not always follow the multidrug therapy regimens recommended by the World Health Organization (WHO) or the frequently recommended regimens in the United States. 1, 3 Therefore, an appropriate course of therapy was based upon the initial treating physician's conclusion that an adequate course of therapy had been completed. We documented age at diagnosis, gender, race, disease classification, number of drugs prescribed, length of treatment, and time to relapse or last follow-up. Hansen's disease was categorized as multibacillary (MB) or paucibacillary (PB) by the WHO classification. Fifty-six (49.6%) of the 113 patients with Hansen's disease were still receiving therapy. Therapy was discontinued and there was no evidence of treatment failure in 46 (40.7%) of the 113 patients. For the remaining 11 (9.7%) of the 113 patients, treatment had been discontinued and therapy was then restarted. Of the 11 patients, two were believed to be reversal reactions but were also treated for relapse. The other nine were treated for presumed treatment failure based upon clinical signs or symptoms. During the initial treatment courses in the 11 patients with treatment failures, eight had been treated with two or more drugs effective against Hansen's disease. Table 1 shows the similarities between those patients who were re-treated and those not receiving therapy.
We evaluated each patient for medication adherence, clinical signs and symptoms of relapse, and bacteriologic status. Repeat therapy for true relapse was used by only two of the 11 patients with Hansen's disease. The remaining nine patients (5 MB and 4 PB) included two in whom it was retrospectively apparent that they were non-adherent with therapy (defaulters), four who had actually met histologic criteria for reversal reactions (an abrupt increase in inflammations within previously inactive skin lesions or new skin lesions, neuritis, or low-grade fever), two who were treated without repeat biopsies, and one who never actually achieved acid-fast negative smear status. Of the two patients who met the strict definition of relapse, one was a Hispanic male with MB disease who had received five years of dapsone monotherapy in the 1970s and who relapsed 11 years later. The other was a white male who had MB disease and had been treated for five years with multi-drug therapy (dapsone, rifampin, and clofazimine) but who relapsed 13 months after treatment had been stopped.
These data demonstrate that although an appreciable number of patients with Hansen's disease who completed therapy in an area of low endemicity were re-treated (11 of 57, 19.3%), few (2 of the 57, 3.5%) met strict criteria for relapse. Relapse rates range from less than 1% to greater than 40% depending upon the drug regimen, the length of follow-up, and whether relapse was determined by physical examination alone or by skin smears or biopsies. 1, [3] [4] [5] The various treatment regimens prescribed (including some non-standard multi-drug regimens), the co-mingling of MB and PB cases, and the short follow-up time prevents defining a relapse rate in our low endemic population.
The remarkable finding of our review is that nine (82%) of 11 patients with Hansen's disease who were re-treated were exposed to unnecessary medications that could have been avoided by applying strict criteria to the diagnosis of relapse. Our study is limited by its retrospective nature and lack of uniformly managed patients, but the remarkable point is that nine (16%) of the 57 patients with this disease who completed presumably adequate therapy were later mistakenly diagnosed and treated as having relapses. Our data indicate that the application of strict criteria for relapse is essential not only for making therapeutic decisions in the individual pa-tient, but also for the appropriate interpretation of the results of ongoing therapeutic trials for Hansen's disease.
